This week, the case of student Juliana Bardella became famous on social networks and reverberated to the news portals.
According to testimony given by the girl in his page on the social network Facebook, she suffered constant headaches and doctors confirmed that it was migraine. One morning to get ready to go to class, she presented mental confusion and difficulty in performing normal tasks of everyday life, like brushing your teeth and get dressed. When taken to the hospital, several tests were performed and the diagnosis given by doctors was:. Cerebral Venous Thrombosis
The first question the doctor did was she took birth. This, in case it was the cause of thrombosis in Juliana.
After the popularization of history, the National Health Surveillance Agency (Anvisa) issued a statement warning of the risks of this type of contraceptive and the importance to carry out monitoring with the gynecologist.
According to the regulator, the risk of clot formation depends on the type of hormone progesterone present in the drug. Women who use contraceptive containing drospirenone, desogestrel or gestodene have a risk four to six times greater risk of developing venous tromboelismo, in a year than women who do not use combined hormonal contraceptives.
Therefore, it is essential that the medical review family history and ask a series of tests such as breast, liver, extremities and pelvic organs. The clinical evaluation should be performed annually.
Anvisa also states that the benefits of contraception in pregnancy prevention continue to overcome its risks.
Anvisa has no legislation that would force doctors to notify adverse events related to drugs. The same applies to citizens. However, the notification for hospitals and health services is mandatory.
However, if the citizen or health professional observe any adverse reaction in the body which may have been caused by birth, it is important to make this notification to ANVISA.
To this end, the agency has a number of communication channels available, such as Notivisa, entity reporting system, the ombudsman (email@example.com) and Anvisa Meets (0800 642 9782).